Prescription-Event Monitoring

Pharmacoepidemiology, Fifth Edition

Volumn , Issue , 2012, Pages 301-330

  Layton, Deborah ^a   Shakir, Saad A W ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

Disease epidemiology; Drug utilization; Long latency adverse reaction; Modified PEM; Pharmacogenetics; Pharmacovigilance; Prescription event monitoring (PEM); Risk management; Self controlled method; Signal detection

Indexed keywords

EID: 84888747145     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959946.ch20     Document Type: Chapter

References (63)

1. Lenz W, Knapp K. Thalidomide embryopathy. Arch Environ Health 1962; 5: 100-5.
2. Committee on Safety of Drugs. Report for 1969 and 1970. London: HMSO, 1971.
3. Sachs RM, Bortnichak EA. An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 1986; 81(5B): 49-55.
4. Finney DJ. The design and logic of a monitor of drug use. J Chron Dis 1965; 18: 77-98.
5. Wright P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J 1975; 1(5958): 595-8.
6. Inman WHW. Postmarketing surveillance of adverse drug reactions in general practice. I. Search for new methods. Br Med J 1981; 282: 1131-2.
7. Inman WHW. Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription -event monitoring at the University of Southampton. Br Med J 1981; 282: 1216.
8. Council for International Organizations of Medical Sciences (CIOMS), World Health Organization (WHO). International Ethical Guidelines for Biomedical Research Involving Human Subjects, 2002. http://www.cioms.ch/publications/layout_guide2002. pdf (accessed July 2011).
9. Royal College of Physicians of London. Guidelines on the Practice of Ethical Committees in Medical Research involving Human Subjects. London: RCP, 1996.
10. Department of Health. Supplementary Operational Guidelines for NHS Research Ethics Committees, November 2000. Multi - centre Research in the NHS the Process of Ethical Review when there is no Local Researcher. http://www.dh.gov.uk/prod_consum_dh/groups/dh_ digitalassets/@dh/@en/documents/digitalasset/dh_ 4014561.pdf(accessed July 2011).
11. General Medical Council. Confidentiality. http://www.gmc-uk.org/static/documents/content/ Confidentiality_0910.pdf(accessed July 2011).
12. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2005; 14: 589-95.
13. National Information Governance Board. Register of Approved Section 251 Applications. http://www. nigb.nhs.uk/s251/registerapp (accessed July 2011).
14. European Medicines Agency. ICH Topic E2D Post Approval Safety Data Management. Step 5.Note for guidance on definitions and standards for expedited reporting. 2004 (CPMP/ICH/3945/03). http:// www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500002807.pdf(accessed July 2011).
15. Strom B. Sample size considerations for pharmacoepidemiology studies. In: Strom B, ed. Pharmacoepidemiology, 2nd edn. Chichester, UK: John Wiley and Sons, 1994.
16. Machin D, Campbell M, Fayers P, Pinol A. Sample Size Tables for Clinical Studies, Table 7.1. Oxford, UK: Blackwell Science, 1997, p. 150.
17. Machin D, Campbell M, Fayers P, Pinol A. Sample Size Tables for Clinical Studies, Table 7.2. Oxford, UK: Blackwell Science, 1997, pp. 151-3.
18. Wilton LV, Stephens MD, Mann RD. Visual field defect associated with vigabatrin: observational cohort study. BMJ 1999; 319: 1165-6.
19. Layton D, Marshall V, Boshier A, Friedmann P, Shakir SA. Serious skin reactions and selective COX -2 inhibitors: a case series from prescription -event monitoring in England. Drug Saf 2006; 29: 687-96.
20. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MD, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: a non -interventional observational cohort study in 14,772 patients. Br J Urol 1996; 78: 379-84.
21. Pearce HM, Layton D, Wilton LV, Shakir SA. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol 2005; 60: 98-102.
22. Buggy Y, Layton D, Fogg C, Shakir SA. Safety profile of oxcarbazepine: Results from a prescription -event monitoring study. Epilepsia 2010; 51: 818-29.
23. Layton D, Wilton L, Shakir SA. Examining the tolerability of the non -sedating antihistamine desloratadine: a prescription -event monitoring study in England. Drug Saf 2009; 32: 169-79.
24. Osborne V, Layton D, Perrio M, Wilton L, Shakir SA. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf 2010; 33: 579-91.
25. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription -event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf 2009; 32: 409-18.
26. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998; 105: 882-9.
27. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non -compliance with prescribed medication in primary care. BMJ 1993; 307: 846-8.
28. Layton D, Clark DW, Pearce GL, Shakir SA. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001; 57: 167-76.
29. Layton D, Heeley E, Shakir SA. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription -Event Monitoring data. J Clin Pharm Ther 2004; 29: 171-81.
30. Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf 2006; 29: 897-909.
31. Acharya NV, Pickering RM, Wilton LW, Shakir SA. The safety and effectiveness of newer antiepileptics: a comparative postmarketing cohort study. J Clin Pharmacol 2005; 45: 385-93.
32. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 2004; 93: 796-801.
33. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58: 635-41.
34. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 2003; 12: 551-8.
35. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non -experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-7.
36. Stephens MDB, Wilton LV, Pearce G, Mann RD. Visual field defects in patients taking vigabatrin. Pharmacoepidemiol Drug Saf 1997; 6 (Suppl. 2): S18.
37. Layton D, Wilton LV, Shakir SA. Safety profile of celecoxib as used in general practice in England: results of a prescription -event monitoring study. Eur J Clin Pharmacol 2004; 60: 489-501.
38. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10: 577-81.
39. Osborne V, Layton D, Tong E, Shakir SA. Safety of Atrovent CFC -free MDI (metered dose inhaler): An example of protopathic bias in observational cohort studies (oral presentation). 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, Aug. 2011. In press.
40. Kasliwal R, Cornelius V, Wilton LW, Shakir SAW. Abstract no: 255. Combined Pioglitazone -Insulin Use: Analysis from the Pioglitazone PEM Study. 24th International Conference on Pharmacoepidemilogy and Therapeutic Risk Management. Copenhagen, Denmark, August 17 -20, 2008. Pharmacoepidemiol Drug Saf 2008; 17 (Suppl 1): S1-294.
41. Layton D, Heeley E, Hughes K, Shakir SA. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003; 42: 1342-53.
42. Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol 2005; 19: 473-82.
43. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003; 59: 767-73.
44. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-6.
45. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long -term lamotrigine in epilepsy. Epilepsia 1997; 38: 881-6.
46. Heeley E, Wilton LV, Shakir SA. Automated signal generation in prescription -event monitoring. Drug Saf 2002; 25: 423-32.
47. Layton D, Ferreira GLC, Shakir SAW. Abstract no: 305. Integrating pharmacology with pharmacovigilance: developing tools to examine pattern of risks with drug classes in prescription -event monitoring (PEM). 23rd International Conference on Pharmacoepidemiology and Therapuetic Risk management (ISPE), 19 -22th August, 2007, Quebec, Canada. Pharmacoepidemiol Drug Saf 2007; 16 (Suppl S2): S1-S274.
48. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: Retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999; 8: 179-89.
49. Martin RM, Dunn NR, Freemantle SN, Mann RD. Risk of non -fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax 1998; 53: 558-62.
50. Doe C, Fogg C, Layton D, Shakir SAW. Abstract no: 330. Interim results of a modified prescription event monitoring study on ivabradine: case series of utilisation in patients under the age of 40 years, 26th International Conference on Pharmacoepidemilogy and Therapeutic Risk Management. Brighton, England, August 19 -22, 2010. Pharmacoepidemiol Drug Saf 2010; 19 (Suppl 1): S1-S347.
51. Layton D, Riley J, Wilton LW, Shakir S. Safety profile of rofecoxib as used in general practice in England: results of a Prescription -Event monitoring study. Br J Clin Pharmacol 2002; 55: 166-74.
52. Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AC. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX -2 inhibitor users: a cohort study using pharmacy dispensing data in the Netherlands. Drug Saf 2008; 31: 143-58.
53. Flanders WD, Louv WC. The exposure odds ratio in nested case -control studies with competing risks. Am J Epidemiol 1986; 124: 684-92.
54. Aurich-Barrera B, Wilton L, Brown D, Shakir S. Paediatric postmarketing pharmacovigilance using prescription-event monitoring: comparison of the adverse event profiles of lamotrigine prescribed to children and adults in England. Drug Saf 2010; 33: 751-63.
55. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998; 317: 119-20.
56. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 358: 1872-3.
57. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46: 505-11.
58. Fogg C, Kasliwal R, Shakir SA. Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study. Drug Saf 2009; 32: 229-37.
59. Aurich-Barrera B, Wilton LV, Shakir SA. Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription -event monitoring study. Drug Saf 2009; 32: 43-54.
60. Davies MN, Paiba N, Wilton LW, Shakir SAW. Abstract no: P.020. A 12 month modified prescription -event monitoring report for travoprost. 7th Annual conference of ISOP, 21 -24, October, 2007. Bournemouth, England. Drug Saf 2007; 30: 919-90.
61. Perrio MJ, Wilton LV, Shakir SA. A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring. Pharmacoepidemiol Drug Saf 2007; 16: 969-78.
62. Perrio MJ, Wilton LV, Shakir SA. A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance. Drug Saf 2007; 30: 681-95.
63. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996; 143: 1165-73.